Sleep Disorders and Tumor Immune Microenvironment

• Background support Sleep disorders are common in patients with lung cancer, and the incidence is as high as 52.6%-70%, which is related to tumor progression and immunosuppression. Animal experiments have shown that circadian rhythm disruption can reshape the tumor microenvironment, suppress immune responses (such as macrophage dysfunction), and lead to accelerated tumor growth.

o Clinical data show that the immune status of lung cancer patients, such as PD-L1 expression, T cell infiltration level, is closely related to treatment response and survival rate. However, there is still a lack of prospective research evidence on how sleep disorders affect the progression of lung cancer by regulating the immune microenvironment.

• Scientific hypothesis

It is hypothesized that sleep disorders (e.g., insomnia, circadian rhythm disruption) affect the tumor immune microenvironment of lung cancer patients through the following mechanisms:

• inhibits the activity of anti-tumor immune cells, such as CD8+ T cells and NK cells;
• promotes the infiltration of immunosuppressive cells (e.g., regulatory T cells, M2 macrophages);
• up-regulates the expression of proinflammatory factors (e.g., IL-6, TNF-α) and inhibits immune checkpoints (e.g., PD-L1), thereby accelerating tumor progression and reducing treatment efficacy.

• Study design and methods
• Study type Prospective cohort study, stratified analysis of sleep disorder group and non-sleep disorder group, followed up for 1-3 years.
• Study subjects
• Inclusion criteria: patients with newly diagnosed stage Ⅲ-Ⅳ non-small cell lung cancer (NSCLC) who had not received systemic therapy (chemotherapy, immunotherapy or radiotherapy);
• Exclusion criteria: patients with serious mental illness, other malignant tumors or receiving sleep medication;
• According to the Pittsburgh Sleep Quality Index (PSQI) score, PSQI≥7 were divided into sleep disorder group, PSQI<7 were divided into control group.

• Core indicators Indicator categories Specific indicators Sleep assessment PSQI score, polysomnography (total sleep time, sleep efficiency, and number of awakenings) 10 Immunological indicators of peripheral blood: CD4+/CD8+ T cell ratio, NK cell activity, IL-6, TNF-α levels; Tumor tissue: PD-L1 expression, tumor infiltrating lymphocytes (TILs) density, macrophage polarization (M1/M2) Clinical outcomes Time to progression (TTP), overall survival (OS), response rate (ORR) Auxiliary indicators: Anxiety and Depression Scale (HADS), quality of life score (EORTC QLQ-C30) 4. Data collection and follow-up
• Baseline data: demographic characteristics, tumor stage, molecular subtype (e.g., KRAS mutation status).6
• Dynamic monitoring: sleep quality, immune indicators and tumor burden (imaging) were evaluated every 3 months;
• Interventions: Non-pharmacological interventions (e.g., cognitive behavioral therapy, light therapy) 2 were implemented in the sleep-disordered group, and changes in immune indicators were observed.

Inclusion criteria

• Patients with newly diagnosed stage III-IV non-small-cell lung cancer (NSCLC) not receiving systemic therapy (chemotherapy, immunotherapy, or radiotherapy)

Exclusion criteria

• Patients with severe mental illness, other malignant tumors, or receiving sleep medication